News and Reports

Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.

For media inquiries, contact
Rachel Steinhardt
​Vice President of Communications

T 1 212 450 1582

Ludwig in the news


Jul 21, 2017

American Association for Cancer Research
“A key challenge in cancer immunotherapy is to understand why some patients respond to immunotherapy but many others do not,” says Ludwig Brussels Director Benoit Van den Eynde. In a new study, covered by AACR, Van den Eynde and colleagues provide a rationale for testing anti-PD1 immunotherapy in combination with COX-2 inhibitors in the clinic to improve responses.

Jun 02, 2017

Companies like iTeos, founded by Ludwig Cancer Research, are testing IDO inhibitors to boost cancer immunotherapy. Founded by Ludwig with the de Duve Institute at the Université catholique de Louvain in Belgium, iTeos is led by a team experienced in tumor immunology, immunotherapy, drug discovery, business development and entrepreneurship.

Mar 14, 2017

Ludwig MSK’s Dmitriy Zamarin spoke with Targeted Oncology about ways to make immunotherapy more effective in gynecological cancers. Zamarin says success will require combination approaches, biomarker development and identifying subpopulations that are more likely to benefit from immunotherapy.


Nov 10, 2016

Researchers led by Ludwig MSK's Taha Merghoub reported how a targeted drug can reverse the effects of certain immune cells that suppress responses to cancer immunotherapy. ​"We can now potentially identify patients whose tumors possess immune suppressor cells and add a drug to their treatment regimen to specifically disarm them," Merghoub tells GEN.

Aug 04, 2016

WNYC - The Brian Lehrer Show
Ludwig MSK scientist Jedd Wolchok discusses innovative ways that doctors are using the immune system to treat cancer.

Jul 20, 2016

A new Nature study co-authored by Irv Weissman, director of Ludwig Stanford, found that the “don’t eat me” signal many tumor cells display on their surfaces to evade immune system attack - called CD47 -  also appears to play a role in enabling atherosclerosis, the process underlying heart attacks and strokes. Stanford’s Scope blog explains the significance of these findings. 

Jul 07, 2016

Ludwig Johns Hopkins scientist Luis Diaz spoke to Bloomberg about how a cancer patient's response to immunotherapy is tied to the number of mutations in tumor cells.

May 18, 2016

Stanford Medicine's Scope blog
Ludwig Stanford scientist Crystal Mackall shares her research and weighs in on recent successes in the field, stating that immunotherapy is "the biggest thing to hit cancer in the last decade and likely will dominate the next."

Apr 17, 2016

The Washington Post
Researchers led by Ludwig Harvard scientist Stephen Hodi reported at the AACR Annual Meeting that 34 percent of patients with advanced melanoma who were treated the immunotherapy nivolumab alone were still alive five years later.

Apr 17, 2016

Ludwig Harvard scientist Stephen Hodi discussed the results of the longest follow-up survival study conducted to date on patients with advanced melanoma who were treated with the PD-1 inhibitor nivolumab.

Feb 24, 2016

MedCity News
Forty Seven, a clinical-stage immuno-oncology company founded by Ludwig Stanford director Irv Weissman, announced that it has completed the first half of a $75 million financing round and has licensed the rights to multiple immuno-oncology programs from Stanford University.


Oct 22, 2015

Memorial Sloan Kettering's On Cancer blog

Jun 11, 2015

Agence Télégraphique Suisse

Feb 20, 2015

Cancer Discovery

Feb 10, 2015

The Leonard Lopate Show, WNYC


Jul 21, 2014

TEDxTimesSquare - by Ludwig MSK's Jedd Wolchok

Apr 23, 2014

Scientific American - by Ludwig MSK’s Jedd Wolchok